{'fraction_non_alphanumeric': 0.02531645569620253, 'fraction_numerical': 0.005842259006815969, 'mean_word_length': 5.718954248366013, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Beta-receptor blockers: metabolic actions and therapeutic consequences (author's transl)].

Whereas the control of cardiac function occurs through the sympathetic nervous system via the beta 1-receptors, metabolic processes are controlled via beta 1- and/or beta 2-receptors accordingly. The inhibition occurring during the use of non-selective beta-receptor blockade of the beta 2-receptors also consequently leads undesirably to possible impairment of insulin secretion and especially to glycogenolysis in the skeletal musculature. The initially more intensely inhibited lipolysis under mixed beta-receptor blockade lead among other things to more severe changes in the lipoproteins than a predominantly beta 1-selective receptor blockade through reactive compensation procedures. Generally in the treatment of arterial hypertension, as also of cardiovascular disease with beta-receptor blocker, a beta 1-receptor blocker is preferred in order to avoid as far as possible disadvantageous metabolic actions of such treatment.